Becton Dickinson Forecasts Higher Sales From COVID-19 Diagnostic Testing Revenues
Becton Dickinson and Co (NYSE: BDX ) reported Q3 FY22 revenues of $4.6 billion , up 0.7% Y|Y (3.8% on a currency-neutral basis), better than the consensus of $4.47 billion. Revenue was driven by base revenue growth of 6% as reported, 9.3% currency-neutral. COVID-only testing revenues of $76 million declined from $300 million in the prior year. Medical … Full story available on Benzinga.com
Becton Dickinson Forecasts Higher Sales From COVID-19 Diagnostic Testing Revenues
Becton Dickinson and Co (NYSE: BDX ) reported Q3 FY22 revenues of $4.6 billion , up 0.7% Y|Y (3.8% on a currency-neutral basis), better than the consensus of $4.47 billion. Revenue was driven by base revenue growth of 6% as reported, 9.3% currency-neutral. COVID-only testing revenues of $76 million declined from $300 million in the prior year. Medical … Full story available on Benzinga.com